Trends in antibacterial use in US academic health centers: 2002 to 2006

Archives of Internal Medicine

Volumn 168, Issue 20, 2008, Pages 2254-2260

  Pakyz, Amy L ^a   MacDougall, Conan ^b   Oinonen, Michael ^c   Polk, Ronald E ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c University HealthSystem Consortium   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIINFECTIVE AGENT; CARBAPENEM; CEFACLOR; CEFALEXIN; CEFAZOLIN; CEFOTAXIME; CEFOTETAN; CEFOXITIN; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; DICLOXACILLIN; DOXYCYCLINE; NAFCILLIN; OXACILLIN; PENICILLIN G POTASSIUM; PENICILLIN G SODIUM; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLONE DERIVATIVE; SULTAMICILLIN; TETRACYCLINE; TIMENTIN; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; HEALTH CARE POLICY; HEALTH CARE SYSTEM; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PRIORITY JOURNAL; UNITED STATES; UNIVERSITY HOSPITAL;

ACADEMIC MEDICAL CENTERS; ADULT; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; CARBAPENEMS; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; HUMANS; PENICILLANIC ACID; PIPERACILLIN; UNITED STATES; VANCOMYCIN;

EID: 55949093232     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.168.20.2254     Document Type: Article

References (38)

1. Lipsitch M, Samore MH. Antimicrobial use and antimicrobial resistance: a population perspective. Emerg Infect Dis. 2002;8(4):347-354.
2. Cosgrove SE, Kaye KS, Eliopoulous GM, Carmeli Y. Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species. Arch Intern Med. 2002;162(2):185-190.
3. Cosgrove SE. The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. Clin Infect Dis. 2006;42(suppl 2):S82-S89.
4. Siegel JD, Rhinehart E, Jackson M, Chiarello L; Healthcare Infection Control Practices Advisory Committee. Management of multidrug-resistant organisms in healthcare settings, 2006. http://www.cdc.gov/ncidod/dhqp/pdf/ar/ mdroGuideline2006.pdf. Accessed August 4, 2008.
5. Shlaes DM, Gerding DN, John JF, et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Infect Control Hosp Epidemiol. 1997;18(4):275-291.
6. Dellit TH, Owens RC, McGowan JE, et al; Infectious Diseases Society of America; Society for Healthcare Epidemiology of America. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America Guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007;44(2):159-177.
7. Spellberg B, Guidos R, Gilbert D, et al. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis. 2008;46(2):155-164.
8. Carling PC, Fung T, Coldiron JS. Parenteral antibiotic use in acute-care hospitals: a standardized analysis of fourteen institutions. Clin Infect Dis. 1999;29(5):1189-1196.
9. Polk RE, Fox C, Mahoney A, Letcavage J, MacDougall C. Management of adult antibacterial drug use in 130 US hospitals: comparison of defined daily dose and days of therapy. Clin Infect Dis. 2007;44(5):664-670.
10. Bhavnani SM. Benchmarking in health-system pharmacy: current research and practical applications. Am J Health Syst Pharm. 2000;57(suppl 2):S13-S20.
11. MacDougall C, Polk RE. Variability in rates of use of antibacterials among 130 US hospitals and risk-adjustment models for interhospital comparison. Infect Control Hosp Epidemiol. 2008;29(3):203-211.
12. Fridkin SK, Steward CD, Edwards JR, et al; Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) Hospitals. Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2. Clin Infect Dis. 1999;29(2):245-252.
13. National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System Report: data summary from January 1992 through June 2004: issued August 2004. Am J Infect Control. 2004;32(8):470-485.
14. Fridkin SK, Lawton R, Edwards JR, Tenover FC, McGowan JE, Gaynes RP; Intensive Care Antimicrobial Resistance Epidemiology Project; National Nosocomial Infections Surveillance Systems Hospitals. Monitoring antimicrobial use and resistance: comparison with a national benchmark on reducing vancomycin use and vancomycin-resistant enterococci. Emerg Infect Dis. 2002;8(7):702-707.
15. Arnold LM, Crouch MA, Carroll NV, Oinonen M. Outcomes associated with vasoactive therapy in patients with acute decompensated heart failure. Pharmacotherapy. 2006;26(8):1078-1085.
16. Bonk ME, Krown H, Matuszewski K, Oinonen M. Potentially inappropriate medications in hospitalized senior patients. Am J Health Syst Pharm. 2006;63(12):1161-1165.
17. Tacconelli E, De Angelis G, Cataldo MA, Pozzi E, Cauda R. Does antibiotic exposure increase the risk of methicillin-resistant Staphylococcus aureus (MRSA) isolation? a systematic review and meta-analysis. J Antimicrob Chemother. 2008;61(1):26-38.
18. Linder JA, Huang ES, Steinman MA, Gonzales R, Staffor RS. Fluoroquinolone prescribing in the United States: 1995 to 2002. Am J Med. 2005;118(3):259-268.
19. Gasink LB, Fishman NO, Weiner MG, Nachamkin I, Bilker WB, Lautenbach E. Fluoroquinolone-resistant Pseudomonas aeruginosa: assessment of risk factors and clinical impact. Am J Med. 2006;119(6):526.e19-526.e25.
20. Ena J, Dick RW, Jones RN, Wenzel RP. The epidemiology of intravenous vancomycin usage in a university hospital: a 10-year study. JAMA. 1993;269(5):598-602.
21. Kirst HA, Thompson DG, Nicas TI. Historical yearly usage of vancomycin. Antimicrob Agents Chemother. 1998;42(5):1303-1304.
22. Centers for Disease Control and Prevention. Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC).MMWRRecomm Rep. 1995;44(RR-12):1-13.
23. Fridkin SK, Hageman JC, Morrison M, et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med. 2005;352(14):1436-1444.
24. Francis JS, Doherty MC, Lopatin U, et al. Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis. 2005;40(1):100-107.
25. Klevens RM, Morrison MA, Nadle J, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA. 2007;298(15):1763-1771.
26. Tenover FC. Vancomycin-resistant Staphylococcus aureus: a perfect but geographically limited storm? Clin Infect Dis. 2008;46(5):675-677.
27. Wang G, Hindler JF, Ward KW, Bruckner DA. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol. 2006;44(11):3883-3886.
28. Robert J, Bismuth R, Jarlier V. Decreased susceptibility to glycopeptides in methicillin-resistant Staphylococcus aureus: a 20 year study in a large French teaching hospital: 1983-2002. J Antimicrob Chemother. 2006;57(3):506-510.
29. Fridkin SK, Hageman J, McDougal LK, et al. Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin: United States: 1997-2001. Clin Infect Dis. 2003;36(4):429-439.
30. Moise PA, Sakoulas G, Forrest A, Schentag JJ. Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2007;51(7):2582-2586.
31. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med. 2006;166(19):2138- 2144.
32. Soriano A, Marco F, Martínez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2008;46(2):193-200.
33. Deresinski S. Counterpoint: vancomycin and Staphylococcus aureus: an antibiotic enters obsolescence. Clin Infect Dis. 2007;44(12):1543- 1548.
34. Lewis JS II, Ellis MW. Approaches to serious methicillin-resistant Staphylococcus aureus infections with decreased susceptibility to vancomycin: clinical significance and options for management. Curr Opin Infect Dis. 2007;20(6):568-573.
35. Patel JB, Jevitt LA, Hageman J, McDonald LC, Tenover FC. An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus. Clin Infect Dis. 2006;42(11):1652-1653.
36. Rice LB. The Maxwell Finland Lecture: for the duration: rational antibiotic administration in an era of antimicrobial resistance and Clostridium difficile. Clin Infect Dis. 2008;46(4):491-496.
37. Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol. 2005;58(4):323-337.
38. Sherman ER, Heydon KH, St John KH, et al. Administrative data fail to accurately identify cases of healthcare-associated infection. Infect Control Hosp Epidemiol. 2006;27(4):332-337.